Category: Press Releases

SHANGHAI, China, Oct. 27, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the presentation of new clinical trial results at the European Society of Oncologists (“ESMO”) Immuno-Oncology Congress 2023, an international conference held in Madrid, Spain, from October 20^th to 24^th. At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters. These trials encompass ten diverse fields, including lung cancer, kidney cancer, head and neck cancer, breast cancer, colorectal cancer, cervical cancer, thymus cancer, and lymphoma.

“This year’s ESMO Congress highlighted the most recent results from 11 clinical studies conducted with our core product, toripalimab,” said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences. “Among these studies, the results of EXTENTORCH study involving small cell lung cancer and the RENOTORCH study focusing on renal cell carcinoma were presented for the first time. As ‘PD-1+X’ combination therapy achieves further clinical advancement across multiple indications, it will further bolster Junshi Biosciences’ extensive immuno-oncology pipeline, one that has been cultivated through many years of dedication.”

The RENOTORCH Study: Median PFS reaches 18.0 months! Record-setting results for 1^st line immunotherapy in advanced kidney cancer

Led by Professor Jun GUO of Beijing Cancer Hospital and Professor Yiran HUANG of Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine, RENOTORCH is China’s first phase III clinical study to focus on immunotherapy for advanced renal cell carcinoma. Study findings were unveiled for the first time during a proffered paper session at the ESMO Congress. Professor Xinan SHENG of Beijing Cancer Hospital gave a comprehensive overview of the research results in the oral presentation. The full manuscript of the study has also been published in Annals of Oncology (Impact factor 51.8) on the day of presentation.

The RENOTORCH study (NCT04394975) is a randomized, open-label, multicenter phase III clinical study that enrolled 421 patients from 47 medical centers with intermediate to high-risk unresectable or metastatic renal cell carcinoma (RCC) who had received no prior systematic treatment. RENOTORCH is the first pivotal phase III study of immunotherapy for advanced RCC in China.

As of March 31, 2023 (median follow-up time of 14.6 months), the RENOTORCH interim analysis results demonstrated that when compared to sunitinib monotherapy, toripalimab combined with axitinib significantly improved the patients’ progression-free survival (PFS) and objective response rate (ORR) while maintaining a manageable safety profile.

According to assessments by the independent review committee (IRC), the median PFS was 18.0 months in the toripalimab-axitinib group, nearly double that of the sunitinib group, which had a median PFS of 9.8 months. Toripalimab plus axitinib reduced the risk of disease progression or death by 35% (HR=0.65; 95% CI: 0.49-0.86; P=0.0028) compared to sunitinib. The 1-year and 2-year PFS rates of these two groups were 62.7% vs. 45.4% and 44.6% vs. 30.2%, respectively. Notably, unlike previous studies of a similar nature that included patients across all risk levels, this study only enrolled patients at intermediate to high risk and yet still achieved the longest median PFS ever reported in 1^st line RCC.

When compared to patients in the sunitinib group, toripalimab-axitinib provided a superior ORR (IRC-assessed ORR of 56.7% vs. 30.8%, P<0.001) and a prolonged duration of response (DoR) (median DoR not yet reached vs. 16.7 months; HR=0.614; 95% CI: 0.340-1.137).

At the interim analysis, an OS trend favoring the toripalimab plus axitinib combination over sunitinib monotherapy (median OS not yet reached vs. 26.8 months) has also been demonstrated, with a 39% lower risk of death (HR=0.61; 95% CI: 0.40-0.92). The 1-year and 2-year OS rates of the toripalimab-axitinib group and sunitinib group were 90.5% vs. 81.9% and 71.8% vs. 63.2%, respectively.

The combination had a manageable safety profile and no new safety signals were identified.

In July 2023, based on RENOTORCH’s promising results, the National Medical Products Administration (NMPA) formally accepted the supplemental new drug application for toripalimab plus axitinib as the first-line treatment for patients with unresectable or metastatic RCC.

The EXTENTORCH Study: World’s 1^st PD-1 inhibitor to achieve both positive PFS and OS results in phase III SCLC study

EXTENTORCH, a phase III study of toripalimab combined with chemotherapy as first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), made its debut as a late-breaking abstract at the ESMO Congress 2023. The study was led by principal investigator Professor Ying CHENG of Jilin Cancer Hospital, and presented by Professor Ying LIU from Jilin Cancer Hospital at the ESMO Congress.

The EXTENTORCH study (NCT04012606) is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study designed to compare the efficacy and safety of toripalimab vs. placebo in combination with etoposide plus platinum for the first-line treatment of ES-SCLC. EXTENTORCH enrolled a total of 442 ES-SCLC patients who had received no prior systematic treatment from 51 medical centers in China. In May 2023, EXTENTORCH successfully reached its primary endpoints, and toripalimab became the world’s first PD-1 inhibitor to achieve two primary endpoints, OS and PFS, in a phase III study of first-line treatment for ES-SCLC.

The findings from the EXTENTORCH study revealed that compared to chemotherapy alone, toripalimab plus chemotherapy for the first-line treatment of patients with ES-SCLC, coupled with toripalimab monotherapy as maintenance therapy, significantly prolonged PFS and OS while maintaining a manageable safety profile. With these promising results, toripalimab combined with chemotherapy is poised to become a standard first-line therapy for ES-SCLC.

The final PFS analysis (median follow-up time of 11.8 months) demonstrated that compared to chemotherapy alone, toripalimab combined with chemotherapy significantly improved patients’ PFS (researcher-assessed median PFS of 5.8 vs. 5.6 months) while reducing the risk of disease progression or death by 33% (HR=0.667; 95% CI: 0.539-0.824; P=0.0002).

Biomarker analyses revealed that both PFS and OS improved in the toripalimab-chemotherapy group, regardless of the patients’ tumor mutational burden (TMB) status. Additionally, mutations in focal adhesion/integrin pathway were associated with poorer PFS and OS prognoses in patients receiving toripalimab plus chemotherapy.

In terms of safety, toripalimab combined with chemotherapy has a manageable safety profile and no new safety signals were identified.

In July 2023, based on the EXTENTORCH trial results, the NMPA accepted the supplemental new drug application for toripalimab plus etoposide and platinum as the first-line treatment of ES-SCLC.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Four of the company’s innovations have already reached the Chinese or international markets, one of which is China’s first self-developed anti-PD-1 monoclonal antibody, toripalimab. Additionally, more than 30 drugs are currently in clinical development. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI^®, and other novel therapies for the prevention and treatment of COVID-19.

With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs”, Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8967446

ริยาด ซาอุดีอาระเบีย, Oct. 27, 2023 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) นำเสนอแนวทางขั้นสูงในการยกระดับเส้นทางการรักษาผู้ป่วย ที่งานนิทรรศการสุขภาพระดับโลกประจำปี 2566 ในเมืองริยาด โรงพยาบาลแห่งดังกล่าวได้แสดงบทบาทของเครื่องมือดังกล่าวในการยกระดับผลลัพธ์ด้านการดูแลสุขภาพและประสิทธิภาพการดำเนินงานในขอบเขตทางการแพทย์ที่หลากหลายด้วยการควบคุมและใช้ประโยชน์จากโซลูชันการดูแลสุขภาพดิจิทัลที่ล้ำสมัย

KFSH&RC ประสบความสำเร็จอย่างมากในการปรับปรุงกระบวนการรับผู้ป่วยผ่านบริการ ‘Ehalat’ แพลตฟอร์มอัตโนมัตินี้ช่วยลดความยุ่งยากในการส่งต่อทางการแพทย์และส่งเสริมความร่วมมือกับหน่วยงานด้านการดูแลสุขภาพทั้งภาครัฐและเอกชน นอกจากนี้ ยังช่วยให้ผู้ใช้ส่งรายงานทางการแพทย์ รวบรวมข้อมูลส่วนบุคคล และเข้าถึงประวัติทางการแพทย์ได้อีกด้วย ทั้งหมดนี้ได้รวมอยู่ในบริการแบบครบวงจร ทำให้ไม่จำเป็นต้องไปโรงพยาบาลด้วยตนเอง ซึ่งไม่เพียงแต่ช่วยลดความยุ่งยากในการประเมินอาการของผู้ป่วยและสิทธิ์การรักษาเท่านั้น แต่ยังให้การติดตามและอัปเดตแอปพลิเคชันแบบเรียลไทม์อีกด้วย

ในตอนนี้ผู้ป่วยจะสามารถติดตามความคืบหน้าการรักษาได้จากระยะไกลผ่านแอปพลิเคชันมือถือ “Altakhassusi” ซึ่งช่วยให้ผู้ป่วยเข้าถึงเวชระเบียนได้อย่างปลอดภัย แอปนี้ช่วยให้ผู้ป่วยสามารถดูผลการตรวจทางรังสีวิทยาและห้องปฏิบัติการทางการแพทย์ กำหนดเวลาการนัดหมายอย่างง่ายดาย เข้าร่วมเซสชันการติดตามผลเสมือนจริงกับแพทย์ของผู้ป่วย และแม้แต่ประเมินประสิทธิผลของการรักษาของตน นอกจากนี้ แอปยังช่วยยกระดับด้านกระบวนการเติมยาได้โดยไม่ต้องผ่านใบสั่งยา (prescription refills) เวชภัณฑ์ และความต้องการด้านโภชนาการ ทำให้การติดต่อสื่อสารกับทีมแพทย์และโรงพยาบาลเป็นเรื่องง่าย

KFSH&RC มุ่งมั่นที่จะมอบประสบการณ์การรักษาคุณภาพสูงด้วยระบบอัตโนมัติในทุกขั้นตอน แนวทางนี้ช่วยประหยัดเวลาและทำให้ผู้ป่วยไม่ต้องใช้ความพยายามมาก อีกทั้งช่วยปรับปรุงการตัดสินใจทางการแพทย์ผ่านวิธีการและรูปแบบการดูแลที่ทันสมัย ซึ่งใช้ประโยชน์จากความก้าวหน้าอย่างรวดเร็วในนวัตกรรมด้านสุขภาพดิจิทัล ความสามารถเหล่านี้ช่วยให้สามารถบูรณาการเทคโนโลยีทางการแพทย์ต่าง ๆ ได้อย่างราบรื่น และทำให้ผลลัพธ์ทางคลินิก เอกสาร และข้อมูลทางการแพทย์มีความมั่นคงขึ้น โดยความสามารถดังกล่าวมีตั้งแต่บันทึกการผ่าตัดไปจนถึงการดูแลหลังการผ่าตัด การรับรองการไหลเวียนของข้อมูลว่าจะเป็นไปอย่างราบรื่น การเพิ่มประสิทธิภาพการดูแล และการปรับแต่งให้ตรงกับความต้องการเฉพาะของผู้ป่วยแต่ละราย

KFSH&RC ได้รับการยอมรับทั่วโลกในด้านบริการดูแลสุขภาพเฉพาะทางที่ยอดเยี่ยมและนวัตกรรมที่ก้าวล้ำ องค์กรเป็นศูนย์กลางขั้นสูงสำหรับการวิจัยและการศึกษาทางการแพทย์ โดยมุ่งมั่นที่จะพัฒนาเทคโนโลยีทางการแพทย์ และยกระดับมาตรฐานการดูแลสุขภาพในระดับโลก องค์กรมุ่งมั่นที่จะให้บริการระดับโลกในด้านการดูแลทางคลินิก การวิจัย และการศึกษา โดยผ่านความร่วมมือกับสถาบันในระดับท้องถิ่น ระดับภูมิภาค และระดับนานาชาติ

นิทรรศการสุขภาพระดับโลกมีผู้แสดงผลงานที่เข้าร่วมงาน 250 รายจาก 15 ประเทศ จึงถือเป็นงานรวมตัวด้านการดูแลสุขภาพชั้นนำในตะวันออกกลาง โดยนิทรรศการทำหน้าที่เป็นเวทีสำหรับความร่วมมือระหว่างซาอุดิอาระเบียและชุมชนการดูแลสุขภาพระดับโลก ซึ่งถึงผู้ผลิตและซัพพลายเออร์ระดับภูมิภาคและระดับนานาชาติ การประชุมสุดยอดในปีนี้ ซึ่งดำเนินการภายใต้หัวข้อ “การลงทุนด้านสุขภาพ” ให้คำมั่นว่าจะเป็นงานอีเวนต์สำคัญที่กำหนดอนาคตของการดูแลสุขภาพ

ข้อมูลการติดต่อ:kfshrc@mcsaatchi.com

สามารถดูรูปภาพประกอบประกาศนี้ได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/2825a442-d3e8-4c08-aa98-61fb48e4fe5e

GlobeNewswire Distribution ID 8967429

InvtAI

ISTANBUL, Türkiye, Oct. 27, 2023 (GLOBE NEWSWIRE) — Invt.AI, a pioneering AI business assistant platform for businesses and startups, is set to launch a sale of its utility token (ticker: INA) in the upcoming days. The use cases for Ethereum- and Arbitrum-based INA include—but are not limited to—granting access to the platform’s premium features at a discounted price, offering incentives and rewards to data providers and AI engine trainers for providing verified data sources, and introducing staking, yield farming, and DAO initiatives.

One of the company’s core strengths is its Invt.AI Bot and Agent. Available for Telegram and Discord and trainable on the latest or customized data, it is programmed with state-of-the-art AI algorithms, enabling both startups seeking funding and established firms looking to expand to understand user queries, provide real-time market updates, and offer personalized recommendations.

“By leveraging Data Analytics and Machine Learning, Invt.AI’s automatic marketing tools identify customer preferences, segment target markets, and deliver tailored marketing messages,” said Mustafa Syed, the CEO of Invt.AI. “Our goal is to empower businesses to maximize their marketing efforts and achieve higher conversion rates.”

The Invt.AI Token
The Invt.AI’s INA Token serves as the utility for Invt.AI subscriptions and represents the epitome of AI decentralization on the Invt.AI blockchain. INA tokens will serve as a payment utility during the initial stages, providing seamless access to the platform’s premium features and incentivizing active participation within the Invt.AI ecosystem. Additionally, INA tokens will embody governance power, allowing token holders to actively participate in key decision-making processes, shaping the future trajectory of the platform. With the seamless integration of INA tokens, Invt.AI aims to foster a vibrant and engaged community, driving the next wave of innovation in the AI space, backed by the secure and efficient InvtAI blockchain node.

At the time of writing, the whitelisting procedure is already open, allowing early adopters to reserve their spot and enjoy a 40-percent discount. It is also a prerequisite to enrolling in the referral program, which will let participants receive a 6.9% bonus coming from their referees’ contributions.
To join, please follow this link: https://www.invt.ai/ecosystem.

About Invt.AI
With its expertise in AI technologies, strategic guidance, and innovative tools, Invt.AI assists businesses in implementing Artificial Intelligence—from strategy development to deployment and ongoing support—and empowers them to optimize operations, ignite growth, and stay ahead.

Media Contact
LinkedIn: www.linkedin.com/company/invtai
Twitter: www.twitter.com/InvtAI
Telegram: https://t.me/InvestAI_Community
YouTube: www.youtube.com/@InvtAI
Website: www.invt.ai

For any inquiries regarding this press release, please do not hesitate to contact:
Eddie Lee
eddie@invt.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/af80b1ab-e3a3-4590-994f-b67f08ef9847

GlobeNewswire Distribution ID 1000886376

Fabrizio Di Michele, right, President of LaPresse Agency, Marco Durante, middle, and President of Business Care Massimo Veccia, right.

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) — The Consulate General of Italy in New York hosted the awards ceremony for the 6th edition of the ‘Business Care International Award’ on Thursday. The recognition, as explained by the creator of the award and president of Business Care Communication, Massimo Veccia, is awarded every year to the personalities representing the “best contemporary Italian spirit.” New to this year’s edition was the Special Award to the ‘Best Italian Entrepreneur in the United States of America 2023-2024’, awarded to Marco Maria Durante, publisher of the LaPresse news agency. “LaPresse has entered the American market, we have opened a company called LaPresse USA Inc, of which I am President. We have made investments in this country,” commented Durante during the ceremony. “But above all in these last five years we have made a turning point in the company, thanks also to the chief editor Alessia Lautone, who I thank, because she has truly brought about a change in the agency,” added Durante. During the ceremony, which was attended by the Consul General of Italy, Fabrizio Di Michele, the following were awarded: Alberto Milani, president of the Italy-America Chamber of Commerce; Mauro Porcini, chief design officer Pepsico USA; Pasquale Santangeli, cardiologist at the Cleveland Clinic (Cleveland, Ohio); Maria Rita Grieco, deputy director of TG1 Rai; Sally Fischer, president Sally Fischer Public Relations; and Rosario Procino, founder and director of the Ribalta restaurant in New York. Representing the Italian Parliament is the Honorable Christian Di Sanzo, elected in the North America constituency and member of the Productive Activities Commission of the Chamber of Deputies. “It is a selection of truly important excellences, who converge on New York or are based in New York. And the peculiarity of this award is precisely that it brings together personalities from very different backgrounds, who however have had success as Italians. They are people of which we are not only proud of, but with which we try to work and network to promote Italy in New York and in the United States,” said Consul Di Michele. “Once upon a time people emigrated from Italy to America out of necessity, out of poverty, now in search of opportunities,” commented di Sanzo. “These awards are a recognition of the contribution that the new immigration gives to the United States and Italy.”

Translations for Italy-USA: Business Care International Award Ceremony in NY

Fabrizio Di Michele 01:05
Here we colonised the research and academic world. We are great doing business, art and creativity. It is true that we are good at creating network and helping reach others abroad, but the Italians have a tradition of individualism, we can’t change ourselves.

Marco Durante 01:31
Absurd, I take the prize as Italian in New York and in this moment, I represent Italy. This honours me so much because this is my country. I spend 15 days a month here, the rest of the time between Spain, Italy where I have my family between Milan and Rome and also London. It’s evident that Maradona would not win any championship without a great team.

I am lucky to have a great team that brought me and helped me to arrive where we are now. This is a team made of all my employees. For example today there is Marco Liconti, an Italian journalist, our correspondent in Washington who covers the activity of the ambassador Mariangela Zappia. We have another important reality, AP, Associated Press. This has been an important marriage, I believe that this has been the most important moment in my career. If we had not found them maybe I would not be here. They help us a lot, they are here today with the cameras, with the photographers and also this event will be spread all over the world and this will ease our job.

For more information:
Press Office LaPresse – ufficio.stampa@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f972c5c1-6d3a-49fa-805a-5b4ed8560052

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/500183f2-b957-4c36-89d0-d2e2a96ff778

GlobeNewswire Distribution ID 8967400

GMAC’s annual survey reveals new shifts in the underlying expectations of applicants

RESTON, Va., Oct. 27, 2023 (GLOBE NEWSWIRE) — Across the globe, total applications to graduate business school programs in 2023 dipped by approximately five percent. However, more programs than last year reported growth in their applications—indicating that the drop in applications was not felt evenly, according to an annual survey released today by the Graduate Management Admission Council (GMAC). GMAC, a global association representing leading business schools, published findings from the 2023 survey results to provide data and insights to better understand current trends in applications to graduate management education (GME) programs.

Specifically, the decline in applications have centered around those to more selective programs, driving a dip in total global applications while their somewhat selective counterparts reported growth in their applications. Many candidates are still interested in more traditional, competitive full-time programs, but online, hybrid, or evening options were much more likely to report application growth. Interestingly, applicants seeking out top-ranked programs may not necessarily be looking for the same flexibility as the others, but many candidates are more willing to sacrifice prestige for flexibility.

“As post-pandemic attitudes toward work continue shifting and preferences for educational offerings continue evolving, the business school community as a whole is quickly adapting,” said Joy Jones, CEO of GMAC. “From degreed programs to new certificates, concentrations, executive education, and micro-credentials, there is a wealth of options appealing to a wide spectrum of candidates in different stages of career and life. It serves as a testament to how business schools rise to the challenge to meet the needs of today’s business school aspirants who will undoubtedly benefit from graduate business education.”

Other Key Findings:

U.S. and regional trends reflect shifts in international and domestic applications.

While flexibility in delivery methods played an important role in driving the global application trends, in the United States, the international and domestic compositions of program volume turned out to be the key drivers behind the growth seen among their GME programs. After several challenging years with the domestic pipeline—especially after applications leveled off following the pandemic—more U.S. programs reported growth in domestic applications than declines in 2023. In fact, besides the increase seen in 2020 related to the pandemic, the number of U.S. programs reporting application growth reached a decade-long high in domestic applications.

While more than half of the programs in the U.S. experienced growth despite a small dip in overall applications, their counterparts in Europe, Asia, and the Pacific Islands were not as fortunate. Most European programs have faced declining applications over the past three years, with a significant drop (13 percent) in total international applications in 2023. Similarly, programs in Asia and the Pacific Islands have experienced two years of relative application declines, but with a pronounced drop (8 percent) in total domestic applications in 2023.

Applications among women continue to stagnate across degree types and regions.

Over the past five years, the share of female applicants in the U.S., Europe, Asia, the Pacific Islands, Canada and Latin America has hovered around two-fifths. Even though GMAC’s Prospective Students Survey indicates that women tend to be more interested in flexible, online, and hybrid programs, the share of women applying to online, hybrid, weekend, and evening programs is still roughly two-fifths. One silver lining lies in the share of women applicants in the executive MBA. While it is comparatively smallest at 32 percent, most of these programs saw growth in their applications from female candidates in 2023.

“It is encouraging to see more women in executive positions pursue advanced business education that could help strengthen them as leaders in the workplace,” said Ana María Zermeño Padilla, director of academic experience and operations of EGADE Business School at Tecnológico de Monterrey and a GMAC Board member. “There is still much work to be done to appeal to women, especially those earlier in their careers, to take advantage of what graduate business degrees, particularly those with online and flexible modules, could offer.”

Applications from underrepresented U.S. populations hit post-pandemic peak and top pre-pandemic levels.

Since 2014, most U.S. GME programs reported either stability or growth in their applications from underrepresented U.S. populations. Similar to broader U.S. and global trends, applications from these candidates surged alongside the pandemic until 2021 and 2022 when a majority of programs reported declines in applications as the pandemic-related increases leveled off. This year’s survey result, however, shows that 47 percent of U.S. programs reported growth in applications from underrepresented U.S. populations, rebounding by a whopping 18 percentage point from a 10-year low in 2022 and even higher than the pre-pandemic years.

“In the wake of the U.S. Supreme Court ruling on race-conscious admissions, business schools are reexamining their recruitment efforts and admissions strategies to continue enrolling a student body that reflects the diversity of the country and their pool of applicants,” said Sabrina White, vice president of school and industry engagement at GMAC. “As the graduate business school community prepares for impending shifts in how U.S. programs evaluate the experiences of applicants from underrepresented racial and ethnic backgrounds, we hope sharing the data reported by schools over the past decade can help serve as a foundation for how current efforts have – or have not – been effective.”

About the Survey

GMAC’s Applications Trends Survey is the largest and most widely cited survey of its kind, serving the graduate management education community for the past quarter of a century. The 2023 survey collected data on applications received by GME programs for the 2023-2024 academic year. Between June and August, 893 programs at 247 business schools worldwide provided responses. Participating programs are located in 32 countries, including 37 U.S. states and the District of Columbia, and reflect the growing diversity of global GME offerings. The total sample includes 413 MBA programs, 456 business master’s programs, five postgraduate programs (PGP), and 19 doctoral programs. More details about this year’s participating programs can be found in the participant profile section of the report.

About GMAC

The Graduate Management Admission Council (GMAC) is a mission-driven association of leading graduate business schools worldwide. GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry as well as resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test (GMAT) exam is the most widely used graduate business school assessment.

More than 12 million prospective students a year trust GMAC’s websites, including mba.com, to learn about MBA and business master’s programs, connect with schools around the world, prepare and register for exams and get advice on successfully applying to MBA and business master’s programs. BusinessBecause and GMAC Tours are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
Mobile: 202-390-4180
thsu@gmac.com

GlobeNewswire Distribution ID 8966836